Search companies or stocks...
Australian Clinical Labs Limited (ACL) intrinsic value snapshot: our valuation models currently suggest the stock is undervalued, with an estimated 37.2% upside relative to fair value at a market price of $2.86. Unlock the dollar fair value estimate for Australian Clinical Labs Limited with Tickerplace Pro.
Current Price: $2.86
Valuation: Undervalued
Confidence: 8.0/10
How we calculate fair value: We combine DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models to estimate intrinsic value. This figure is for information only - not investment advice - and assumptions may not reflect actual market conditions. We encourage doing your own research or speaking with a financial advisor before making investment decisions.
Search our company database (same as the site header), pick a match, or type a ticker to open its intrinsic value analysis.
The verdict and fair-value gap for Australian Clinical Labs Limited (ACL) are summarised in the intrinsic value snapshot above. This section explains the method: we compare the live market price with modeled fair value using DCF, P/E Multiple, and P/S Multiple approaches. Assumptions can change with new earnings, growth, and discount-rate inputs, so treat the result as a research aid rather than a buy or sell signal. Tickerplace Pro unlocks the dollar fair value used in that comparison.
Use this section for context around the gap, not a third restatement of the top-line verdict. The free snapshot above already shows the percentage gap and market price; the dollar intrinsic value stays behind Tickerplace Pro. When peer links are available for ACL, they appear below so you can open the same fair-value workflow on related names.
Our models calculate the intrinsic value of Australian Clinical Labs Limited (ACL) using DCF, P/E Multiple, and P/S Multiple approaches based on projected cash flows, growth rate, and discount rate. Sign in to Tickerplace Pro to view the full dollar estimate.
Based on our 2026 valuation models, ACL appears undervalued at its current price of $2.86. Our model suggests 37.2% upside potential.
Tickerplace calculates ACL's intrinsic value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We project future cash flows, apply a discount rate that reflects investment risk, and compare the resulting fair value estimate to the current market price.
